drugset / Trial / NCT06418711

ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

NCT06418711

Phase 3 Terminated 132 enrolled Mannkind Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This clinical trial is designed to compare the efficacy and safety of Clofazimine Inhalation Suspension versus placebo when added to guideline-based therapy (GBT)

Timeline

Start
2024-09-11
Primary completion
2025-11-10
Completion
2025-11-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Clofazimine Small molecule 80 mg Inhaled